SURREY, BC / ACCESSWIRE / February 28, 2022 / Eversio Wellness Ltd. ("Eversio" or the "Company"), a privately owned and operated Canadian company with a Health Canada issued Controlled Substances Dealer's Licence, is pleased to announce that they have successfully developed four products of various dosages that have been third party lab verified to consistently contain 1.5% psilocybin. These standardized GMP compliant natural psilocybin products are ready for distribution to researchers, clinical trials, or patients approved for treatment through Health Canada's Special Access Program.
"Today we have achieved the goal we set out to reach two years ago when we began this journey as a privately owned and operated business with big dreams to make a change in available options for healthcare in Canada," said Craig Garden, Co-founder & CEO, Eversio. "Our mission has always been to change lives through fungi. We believe that there is something unique about natural medicine from a real mushroom that you just can't get from anything synthetic. We couldn't be more proud of our talented team of scientists, including mycologist Dr. Ludovic Le Renard. PhD, and microbiologist Garnet Martens, MSc. for the hard work they have put it to bring this new category of natural medicines to those in need."
ABOUT EVERSIO WELLNESS LTD.
Eversio Wellness is an expanding mushroom wellness company with a mission to change lives through fungi. Our hope is to foster a world that seeks natural options to help treat the root cause of physical and mental health conditions. We are advocates for overcoming stigma and unlocking the healing powers of the many natural compounds inside psychedelic mushrooms for all. www.eversiowellness.com, www.eversiolabs.com.
CONTACT:
Craig Garden, Co-Founder and CEO, Eversio Wellness Ltd.
craigg@eversiowellness.com
778.608.4200
FORWARD-LOOKING INFORMATION
This news release contains forward-looking information within the meaning of Canadian securities laws regarding the Company and its business, which relate to future events or future performance and reflect management's current expectations and assumptions. Often but not always, forward-looking information can be identified by the use of words such as "expect", "intends", "anticipated", "believes" or variations (including negative variations) of such words and phrases, or state that certain actions, events or results "may", "could", "would" or "will" be taken, occur or be achieved. Such forward-looking statements reflect management's current beliefs and are based on assumptions made by and information currently available to the Company. Readers are cautioned that these forward-looking statements are neither promises nor guarantees, and are subject to risks and uncertainties that may cause future results to differ materially from those expected including, without limitation, risks regarding the Company's ability to bring its products to commercial production, natural health products and digital health industries, and the risks presented by the highly regulated and competitive market concerning the development, production, sale and use of the Company's products. Although the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such information will prove to be accurate, as actual results and future events could differ materially from those anticipated in such information. These forward-looking statements are made as of the date hereof and the Company does not assume any obligation to update or revise them to reflect new events or circumstances save as required under applicable securities legislation.
SOURCE: Eversio Wellness Ltd.
View source version on accesswire.com:
https://www.accesswire.com/690765/Eversio-Wellness-Announces-the-Successful-Development-of-Standardized-Natural-Psilocybin-Products-Ready-for-Patients-in-Trials-or-Health-Canadas-SAP
